Bianchini G - Search Results

1

Spatial predictors of immunotherapy response in triple-negative breast cancer.

Wang XQ, Danenberg E, Huang CS, Egle D, Callari M, Bermejo B, Dugo M, Zamagni C, Thill M, Anton A, Zambelli S, Russo S, Ciruelos EM, Greil R, Győrffy B, Semiglazov V, Colleoni M, Kelly CM, Mariani G, Del Mastro L, Biasi O, Seitz RS, Valagussa P, Viale G, Gianni L, Bianchini G, Ali HR. Wang XQ, et al. Among authors: bianchini g. Nature. 2023 Sep;621(7980):868-876. doi: 10.1038/s41586-023-06498-3. Epub 2023 Sep 6. Nature. 2023. PMID: 37674077 Free PMC article.

2

Introducing new molecular technologies into routine clinical cancer care: is there an impact on the treatment of breast cancer?

Bianchini G, Gianni L. Bianchini G, et al. Ann Oncol. 2008 Sep;19 Suppl 7:vii177-83. doi: 10.1093/annonc/mdn446. Ann Oncol. 2008. PMID: 18790944 Free article. No abstract available.

3

Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, HER2-normal, grade II, lymph node-negative breast cancers.

Kelly CM, Krishnamurthy S, Bianchini G, Litton JK, Gonzalez-Angulo AM, Hortobagyi GN, Pusztai L. Kelly CM, et al. Among authors: bianchini g. Cancer. 2010 Nov 15;116(22):5161-7. doi: 10.1002/cncr.25269. Cancer. 2010. PMID: 20665886 Free article.

4

Prognostic and therapeutic implications of distinct kinase expression patterns in different subtypes of breast cancer.

Bianchini G, Iwamoto T, Qi Y, Coutant C, Shiang CY, Wang B, Santarpia L, Valero V, Hortobagyi GN, Symmans WF, Gianni L, Pusztai L. Bianchini G, et al. Cancer Res. 2010 Nov 1;70(21):8852-62. doi: 10.1158/0008-5472.CAN-10-1039. Epub 2010 Oct 19. Cancer Res. 2010. PMID: 20959472

5

Surrogate markers for targeted therapy-based treatment activity and efficacy.

Bianchini G, Gianni L. Bianchini G, et al. J Natl Cancer Inst Monogr. 2011;2011(43):91-4. doi: 10.1093/jncimonographs/lgr024. J Natl Cancer Inst Monogr. 2011. PMID: 22043050

6

HER2-directed T-cell receptor-mimicking antibody: a "Me Too" or an example of novel antitumor aggressive mimicry?

Bianchini G, Gianni L. Bianchini G, et al. J Natl Cancer Inst. 2013 Feb 6;105(3):161-3. doi: 10.1093/jnci/djs636. Epub 2013 Jan 8. J Natl Cancer Inst. 2013. PMID: 23300218 No abstract available.

7

An unmet need: tailoring extended adjuvant endocrine therapy.

Bianchini G, Gianni L. Bianchini G, et al. Br J Cancer. 2013 Dec 10;109(12):2951-3. doi: 10.1038/bjc.2013.707. Epub 2013 Nov 19. Br J Cancer. 2013. PMID: 24253504 Free PMC article. No abstract available.

8

Research-based PAM50 subtype predictor identifies higher responses and improved survival outcomes in HER2-positive breast cancer in the NOAH study.

Prat A, Bianchini G, Thomas M, Belousov A, Cheang MC, Koehler A, Gómez P, Semiglazov V, Eiermann W, Tjulandin S, Byakhow M, Bermejo B, Zambetti M, Vazquez F, Gianni L, Baselga J. Prat A, et al. Among authors: bianchini g. Clin Cancer Res. 2014 Jan 15;20(2):511-21. doi: 10.1158/1078-0432.CCR-13-0239. Clin Cancer Res. 2014. PMID: 24443618

9

The immune system and response to HER2-targeted treatment in breast cancer.

Bianchini G, Gianni L. Bianchini G, et al. Lancet Oncol. 2014 Feb;15(2):e58-68. doi: 10.1016/S1470-2045(13)70477-7. Lancet Oncol. 2014. PMID: 24480556 Review.

10

Accurate data processing improves the reliability of Affymetrix gene expression profiles from FFPE samples.

Callari M, Lembo A, Bianchini G, Musella V, Cappelletti V, Gianni L, Daidone MG, Provero P. Callari M, et al. Among authors: bianchini g. PLoS One. 2014 Jan 29;9(1):e86511. doi: 10.1371/journal.pone.0086511. eCollection 2014. PLoS One. 2014. PMID: 24489733 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

274 results

Search Page